TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Traws Pharma Inc is not a strong buy for a beginner, long-term investor at this time. The stock is currently in a bearish technical trend, with no significant positive trading signals or catalysts to justify immediate investment. The company's financial performance has been weak, and while there is potential in its flu program, the regulatory challenges and financing risks make it a speculative play. A hold is recommended until clearer signs of recovery or growth emerge.
The stock is in a bearish trend with MACD showing negative momentum (-0.0559), RSI indicating oversold conditions (19.962), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Support levels are at 1.131 and 0.95, while resistance levels are at 1.715 and 1.896. Pre-market price is down 3.31%, reflecting weak sentiment.
The company has secured $60 million in financing to advance its flu program, focusing on tivoxavir as a prophylactic agent. Ladenburg initiated coverage with a Buy rating and a $6.50 price target, citing potential as an alternative to Cidara's CD388.
Regulatory challenges for its flu program and significant pre-market price drop (-3.31%). Weak financial performance in 2025/Q3 with revenue dropping to 0 and net income declining by 64.19% YoY. The stock has an 80% chance of declining 5.99% in the next week.
In 2025/Q3, revenue dropped to 0 (-100% YoY), net income fell to -$3,035,000 (-64.19% YoY), and EPS dropped to -0.34 (-96.14% YoY). Gross margin remained at 100%. Recent FY Non-GAAP EPS was $0.82.
Ladenburg initiated coverage with a Buy rating and a $6.50 price target, highlighting the company's potential in its flu program.
